InvestorsHub Logo
Followers 12
Posts 2336
Boards Moderated 0
Alias Born 04/20/2006

Re: blue_skies post# 1050

Monday, 11/29/2021 1:34:53 PM

Monday, November 29, 2021 1:34:53 PM

Post# of 1140
If it is a Vaccine a better manufacturing process could possibly produce fewer elements that could cause undesirable reactions.
The main feature with C1 is a higher yield with less cost. Couple that with a delivery system such as the Sorrento Therapeutics SOFUSA LYMPHATIC DELIVERY SYSTEM which can lower the dose to 10% needed by an IV delivery and that can drive the retail product cost down and widen the available market considerably.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DYAI News